Wave Chasing Huntington’s Accelerated Approval Based On Caudate Atrophy Surrogate
Executive Summary
The biotech plans a pivotal trial that would support accelerated approval of the Takeda-partnered antisense oligonucleotide, WVE-003, and will discuss it with regulators before the end of the year.